Chang Gung University

National Health Research Institutes

Chung Yuan Christian University

Far East Bio-tec Co., Ltd.

Chang Gung Memorial Hospital, Linkou

Shin-Ru Shih

Jyh-Haur Chern

Yu-An Kung

Tsu-An Hsu

Chia-Liang Tai

Yen-Chun Lee

Chung-Chi Lee

Sheng-Yu Huang

Chuan-Tien Hung

Chih-Shiang Chang

Chiung-Tong Chen

Kak-Shan Shia

Tzong-Yuan Wu

Yi-Hsiang Chen

Ying-Ju Chen

Suey-Sheng Kao

Chuang-Chun Chiuh

Tzyy-Rong Jinn

Yu-Nong Gong

Peng-Nien Huang

Shin-Jhan Zeng

Shu-Jen Chen

Ming-Chu Hsu

Wen-Tai Li

Chung-Ming Chang

Chih-Ching Wu

Hsin-Ping Chiu

Huan-Jung Chiang

I-Chen Hu

Chi-Jene Chen

Chiung-Guei Huang

Wei Chen

Chung-Guei Huang

Gi-Kung Chang

Rei-Lin Kuo

Kar-Yee Yu

Jing-Yun Chen

Hou-Chen Lee

Guang-Wu Chen

Kuan-Ting Liu

Ya-Chun Liao

Xin-Wen Huang

Shau-Feng Chang

A method for determining immune competence against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) includes obtaining a blood sample from a subject in need thereof, detecting, in the blood sample, levels of binding antibodies against SARS-CoV-2 spike S1 protein and its receptor binding domain (RBD), and calculating a weighted value using a regression model. Another method for determining immune competence against SARS-CoV-2 is also disclosed.

Method for determining immune competence against severe acute respiratory syndrome coronavirus 2

Disclosed herein is a method for inhibiting virus infection, including administering to a subject in need thereof an effective amount of a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting viral replication, including contacting a virus with a ferroptosis inhibitor or a pharmaceutically acceptable salt thereof.

Method for inhibiting virus infection and replication

Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.

Recombinant polypeptides derived from FBP1 and FBP2 and uses of the same

The present disclosure provides various cyanobacterial extracts exhibiting antiviral activity to a wide spectrum of viruses, such as enterovirus (EV), respiratory syncytial virus (RSV), Human Herpesvirus (HHV), Ebola virus, porcine epidemic diarrhea virus (PEDV), and porcine reproductive and respiratory syndrome virus (PRRSV). The cyanobacterial extract is prepared from biomass of(or). Also disclosed herein are process for preparing the cyanobacterial extract and uses of the cyanobacterial extract.

Antiviral arthrospira maxima extract

Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a) mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria; (b) freezing the suspension with a temperature below 0&#xb0; C. to form a ice block and the ice block being melted at a low temperature, the whole step being repeated at least twice; (c) separating the cyanobacterial residues and extract solution of the suspension; and (d) collecting the isolated cyanobacterial extract solution; wherein the cyanobacterial extract solution is a solution containing cyanobacterial bioactive substances. The pharmaceutical composition is able to effectively inhibit binding of sialic acid and hemagglutinin of influenza A and/or B virus, so as to inhibit infection and replication of influenza virus. Further, this pharmaceutical composition is able to inhibit infection of influenza virus resistant to neuraminidase inhibitors.

Pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof

A method of treating Influenza A is disclosed. The method includes the step of administering a pharmaceutical composition including an oligonucleotide complementary to a corresponding segment of the nucleotide sequence of microRNA-1290 (miR-1290) (SEQ ID NO: 1) to a subject suffering from Influenza A, wherein at least one of the nucleotides in the oligonucleotide is Thymidine phosphate.

Method of treating influenza A

The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.

Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation

This invention relates to compounds of the following formula: in which R, R, A, A, X, Y, m, n, p, x and y are as defined herein, pharmaceutical compositions comprising the compounds and use of the compounds in treating enterovirus infection.

Imidazolidinone compounds

Use of biscistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation

Compounds of the following formula: in which R, R, A, A, X, Y, m, n, p, x and y are as defined herein. Also disclosed are pharmaceutical compositions each containing one or more of these compounds, and use thereof in treating enteroviral infection.

Anti-enterovirus compounds

Growing community of inventors

Taoyuan, Taiwan

Shin-Ru Shih